CUSIP 75383L102COMRAPPQ4 2025
16 filings · latest Feb 17, 2026
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Trv Gp V, LLC | 7.14M | $216.48M |
| 2 | Fmr LLC | 7.11M | $215.77M |
| 3 | Arch Venture Management, LLC | 3.73M | $113.13M |
| 4 | Capital International Investors | 3.40M | $103.23M |
| 5 | Cormorant Asset Management, LP | 3.03M | $91.85M |
| 6 | Goldman Sachs Group Inc | 3.00M | $91.08M |
| 7 | Blackrock, Inc. | 2.43M | $73.78M |
| 8 | Sofinnova Investments, Inc. | 1.90M | $57.78M |
| 9 |
| 4 | Oct 22, 2025 | Johnson &Amp; Johnson | 13G/A | 4.9% | 1.78M | SEC |
| 5 | Sep 18, 2025 | Sofinnova Venture Partners Xi, L.P. ("Svp Xi") | 13D/A | 4.2% | — | SEC |
| 6 | Feb 13, 2025 | Third Rock Ventures V, L.P. | 13G | 19.5% | 7.14M | SEC |
| 7 | Nov 14, 2024 | Cormorant Asset Management, LP | 13G/A | 8.0% | 2.94M | SEC |
| 8 | Nov 14, 2024 | Arch Venture Fund Xii, L.P. | 13G | 10.2% | 3.73M | SEC |
| 9 | Nov 13, 2024 | Capital International Investors | 13G | 7.1% | 2.60M | SEC |
| 10 | Nov 12, 2024 | Fmr LLC | 13G/A | 15.0% | — | SEC |
See the full Schedule 13D/13G history for Rapport Therapeutics Inc.
Unlock full history| Vanguard Group Inc |
| 1.82M |
| $55.15M |
| 10 | Johnson & Johnson | 1.78M | $54.14M |